Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Hematological Consequences of Valproic Acid in Pediatric Patients: A Systematic Review with a Mechanistic Approach

Author(s): Bamdad Riahi-Zanjani, Mohammad Delirrad, Rana Fazeli-Bakhtiyari, Mahood Sadeghi, Hadi Zare-Zardini, Abbas Jafari* and Adel Ghorani-Azam*

Volume 21, Issue 4, 2022

Published on: 11 August, 2021

Page: [316 - 325] Pages: 10

DOI: 10.2174/1871527320666210811162345

Price: $65

Abstract

Purpose: Although Valproate (VPA) has several advantages in controlling seizures, it may cause serious hematological consequences. Hematotoxicity of VPA is particularly important in pediatrics because patients at this age are at a growing risk of leukemia. For a conclusive agreement about the toxicity of VPA, in this study, we systematically reviewed the literature in which the hematological consequences of VPA had been emphasized.

Methods: A systematic literature search was performed in June 2021 on electronic databases to find original research on the association between VPA therapy and hematotoxicity in pediatric patients. For this purpose, the following search terms “hematotoxicity”, “valproic acid” and “pediatrics” with different spellings and similar terms, were searched in the title, keywords, and abstracts of articles. The data were collected and used for qualitative data description.

Results: A total of 36 relevant articles with an overall 1381 study population were included. The results showed that VPA could cause severe hematotoxicity in children even at therapeutic doses. Neutropenia, thrombocytopenia, and bone marrow depression are the most common complications associated with VPA therapy. Also, findings showed that after discontinuation of VPA and starting other antiepileptic drugs or reducing the administered VPA dose, hematologic damages were entirely resolved, and all the hematological parameters improved during two weeks.

Conclusion: This review showed that VPA therapy could cause hematotoxicity in children; hence, it is recommended to monitor hematological indices during VPA therapy. Also, according to the suggested mechanistic pathways of VPA side effects, a combination of VPA with antioxidants may reduce hematological side effects.

Keywords: Valproic acid, valproate (VPA), hematological consequences, hematotoxicity, children, pediatric patients.

« Previous Next »
Graphical Abstract

[1]
Proença P, Franco JM, Mustra C, et al. An UPLC-MS/MS method for the determination of valproic acid in blood of a fatal intoxication case. J Forensic Leg Med 2011; 18(7): 320-4.
[http://dx.doi.org/10.1016/j.jflm.2011.06.003] [PMID: 21907937]
[2]
Vlase L, Popa D-S, Muntean D, Leucuta S. A new high-throughput LC-MS/MS assay for therapeutic level monitoring of valproic acid in human plasma. Sci Pharm 2008; 76(4): 663-72.
[http://dx.doi.org/10.3797/scipharm.0808-12]
[3]
Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16(10): 695-714.
[http://dx.doi.org/10.2165/00023210-200216100-00004] [PMID: 12269862]
[4]
Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16(10): 669-94.
[http://dx.doi.org/10.2165/00023210-200216100-00003] [PMID: 12269861]
[5]
Sepahi S, Riahi-Zanjani B, Ghorani-Azam A. Effect of valproic acid on metabolic status and endocrine system in pediatric patients with epilepsy: systematic literature review. Rev Clin Med 2017; 4(1): 7-13.
[6]
Farkas V, Szabó M, Rényi I, Kohlhéb O, Benninger C. Temporary pure red-cell aplasia during valproate monotherapy: clinical observations and spectral electroencephalographic aspects. J Child Neurol 2000; 15(7): 485-7.
[http://dx.doi.org/10.1177/088307380001500713] [PMID: 10921523]
[7]
Hauser E, Seidl R, Freilinger M, Male C, Herkner K. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 1996; 18(2): 105-9.
[http://dx.doi.org/10.1016/0387-7604(95)00139-5] [PMID: 8733899]
[8]
Bűdi T, Tóth K, Nagy A, et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia 2015; 56(6): 849-55.
[http://dx.doi.org/10.1111/epi.13011] [PMID: 25967074]
[9]
Allarakhia IN, Garofalo EA, Komarynski MA, Robertson PL. Valproic acid and thrombocytopenia in children: a case-controlled retrospective study. Pediatr Neurol 1996; 14(4): 303-7.
[http://dx.doi.org/10.1016/0887-8994(96)00052-5] [PMID: 8805173]
[10]
Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother 2009; 43(5): 822-30.
[http://dx.doi.org/10.1345/aph.1L617] [PMID: 19401471]
[11]
Kaczorowska-Hac B, Matheisel A, Maciejka-Kapuscinska L, et al. Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report. J Med Case Reports 2012; 6: 239.
[http://dx.doi.org/10.1186/1752-1947-6-239] [PMID: 22883745]
[12]
Manohar C, Avitsian R, Lozano S, Gonzalez-Martinez J, Cata JP. The effect of antiepileptic drugs on coagulation and bleeding in the perioperative period of epilepsy surgery: the Cleveland Clinic experience. J Clin Neurosci 2011; 18(9): 1180-4.
[http://dx.doi.org/10.1016/j.jocn.2011.02.018] [PMID: 21757355]
[13]
Veinot JP, Ruel M. Valproic acid and bleeding: caution required. Ann Thorac Surg 2007; 83(2): 725-6.
[http://dx.doi.org/10.1016/j.athoracsur.2006.07.058] [PMID: 17258035]
[14]
Verrotti A, Greco R, Matera V, Altobelli E, Morgese G, Chiarelli F. Platelet count and function in children receiving sodium valproate. Pediatr Neurol 1999; 21(3): 611-4.
[http://dx.doi.org/10.1016/S0887-8994(99)00060-0] [PMID: 10513686]
[15]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
[http://dx.doi.org/10.1136/bmj.b2700] [PMID: 19622552]
[16]
Wahba A, Bergez E. Severe pancytopenia induced by valproic acid. Cureus 2020; 12(10): e11252.
[PMID: 33269170]
[17]
Ghosh A, Sharma S, Mukhopadhyay S, Bhattacharya A, Choudhury J. Catastrophic presentation of sodium valproate induced pure red cell aplasia in a child with absence seizure. J Hematol Thrombo Dis 2017; 5(265): 2.
[http://dx.doi.org/10.4172/2329-8790.1000265]
[18]
Marija K-P. Valproic acid induced isolated thrombocytopenia after acute respiratory infection. J Epilepsy 2016; 2(1): e106.
[19]
Ray S, Skellett S. Valproate toxicity in a child: Two novel observations. Clin Toxicol (Phila) 2013; 51(1): 60.
[http://dx.doi.org/10.3109/15563650.2012.746694] [PMID: 23170820]
[20]
Dafale SR, Chavan RY, Hungund BR, Kalashetty M, Alatgi A. Acquired pure red cell aplasia in children. J Sci Soc 2012; 39(2): 100.
[http://dx.doi.org/10.4103/0974-5009.101862]
[21]
Elizabeth K, Gopakumar H, Zachariah P, Jacob RG. Valproate induced thrombocytopenia complicating acute febrile illness. Ann Indian Acad Neurol 2006; 9(4): 230-2.
[http://dx.doi.org/10.4103/0972-2327.29206]
[22]
Meyer S, Kuhlmann MK, Peters FT, Limbach HG, Lindinger A. Severe valproic acid intoxication is associated with atrial tachycardia: secondary detoxication by hemoperfusion. Klin Padiatr 2005; 217(2): 82-5.
[http://dx.doi.org/10.1055/s-2004-822676] [PMID: 15770579]
[23]
Yurdaişik G, Uysal S. Valproic Acid-Induced Neutropenia. Ondokuz Mayis Universitesi Tip Dergisi 2002; 19(2): 130-2.
[24]
Bottom KS, Adams DM, Mann KP, Ware RE. Trilineage hematopoietic toxicity associated with valproic acid therapy. J Pediatr Hematol Oncol 1997; 19(1): 73-6.
[http://dx.doi.org/10.1097/00043426-199701000-00011] [PMID: 9065723]
[25]
Brichard B, Vermylen C, Scheiff JM, Ninane J, Cornu G. Haematological disturbances during long-term valproate therapy. Eur J Pediatr 1994; 153(5): 378-80.
[http://dx.doi.org/10.1007/BF01956425] [PMID: 8033931]
[26]
Anzai K, Kitajima H, Kubo M. A case of pure red cell aplasia associated with sodium valproate therapy. Rinsho Ketsueki 1994; 35(3): 286-90.
[PMID: 8158850]
[27]
Kishi T, Fujita N, Kawaguchi H, Ishimae M, Watanabe K, Tanaka T. Bone marrow suppression induced by high dose valproic acid. Arch Dis Child 1994; 71(2): 153-5.
[http://dx.doi.org/10.1136/adc.71.2.153] [PMID: 7944539]
[28]
Rajantie J, Kajosaari M, Ylitalo V. Fatal pancytopenia during high-dose valproate monotherapy. Eur J Pediatr 1992; 151(8): 619.
[http://dx.doi.org/10.1007/BF01957735] [PMID: 1505583]
[29]
Ganick DJ, Sunder T, Finley JL. Severe hematologic toxicity of valproic acid. A report of four patients. Am J Pediatr Hematol Oncol 1990; 12(1): 80-5.
[http://dx.doi.org/10.1097/00043426-199021000-00016] [PMID: 2106802]
[30]
Watts RG, Emanuel PD, Zuckerman KS, Howard TH. Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis. J Pediatr 1990; 117(3): 495-9.
[http://dx.doi.org/10.1016/S0022-3476(05)81105-9] [PMID: 2118175]
[31]
Kawauchi K, Miyano T, Ikeda Y, et al. A report of a case with pure red cell aplasia induced by sodium valproate. Acta Paediatr Jpn 1989; 31(5): 615-9.
[http://dx.doi.org/10.1111/j.1442-200X.1989.tb01364.x] [PMID: 2515743]
[32]
MacDougall LG. Pure red cell aplasia associated with sodium valproate therapy. JAMA 1982; 247(1): 53-4.
[http://dx.doi.org/10.1001/jama.1982.03320260037026] [PMID: 6796707]
[33]
Morris N, Barr RD, Pai KR, Kelton JG. Valproic acid and thrombocytopenia. Can Med Assoc J 1981; 125(1): 63-4.
[PMID: 6790153]
[34]
Jaeken J, van Goethem C, Casaer P, Devlieger H, Eggermont E, Pilet M. Neutropenia during sodium valproate treatment. Arch Dis Child 1979; 54(12): 986-7.
[http://dx.doi.org/10.1136/adc.54.12.986] [PMID: 119491]
[35]
Sandler RM, Emberson C, Roberts GE, Voak D, Darnborough J, Heeley AF. IgM platelet autoantibody due to sodium valproate. BMJ 1978; 2(6153): 1683-4.
[http://dx.doi.org/10.1136/bmj.2.6153.1683] [PMID: 367512]
[36]
El-Ashry R, El-Ayuoty M, Azzam H, El-Naggar M. Effect of antiepileptic drugs on plasma fibrinogen level. Hematol Rep 2020; 12(1)
[http://dx.doi.org/10.4081/hr.2020.7952]
[37]
Oh Y, Joung Y-S, Choi J. Incidence of neutropenia with valproate, antipsychotics, and ADHD medication combination treatment in children and adolescents. J Korean Med Sci 2020; 35(28): e226.
[http://dx.doi.org/10.3346/jkms.2020.35.e226] [PMID: 32686368]
[38]
Baudou E, Benevent J, Montastruc J, Touati G, LeCamus CH. Adverse effects of treatment with valproic acid during the neonatal period. Neuropediatrics 2019; 50(01): 031-40.
[39]
Kurahashi H, Takami A, Murotani K, Numoto S, Okumura A. Decreased platelet count in children with epilepsy treated with valproate and its relationship to the immature platelet fraction. Int J Hematol 2018; 107(1): 105-11.
[http://dx.doi.org/10.1007/s12185-017-2323-0] [PMID: 28879549]
[40]
Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle CE. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis 2008; 19(5): 375-82.
[http://dx.doi.org/10.1097/MBC.0b013e3282f3f9ec] [PMID: 18600085]
[41]
Blackburn SC, Oliart AD, García Rodríguez LA, Pérez Gutthann S. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998; 18(6): 1277-83.
[PMID: 9855327]
[42]
Delgado MR, Riela AR, Mills J, Browne R, Roach ES. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994; 9(3): 311-4.
[http://dx.doi.org/10.1177/088307389400900318] [PMID: 7930412]
[43]
May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993; 34(6): 1098-101.
[http://dx.doi.org/10.1111/j.1528-1157.1993.tb02139.x] [PMID: 8243362]
[44]
Kreuz W, Linde R, Funk M, et al. Valproate therapy induces von Willebrand disease type I. Epilepsia 1992; 33(1): 178-84.
[http://dx.doi.org/10.1111/j.1528-1157.1992.tb02303.x] [PMID: 1733754]
[45]
Barr RD, Copeland SA, Stockwell ML, Morris N, Kelton JC. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982; 57(9): 681-4.
[http://dx.doi.org/10.1136/adc.57.9.681] [PMID: 6812506]
[46]
Richardson SG, Fletcher DJ, Jeavons PM, Stuart J. Sodium valproate and platelet function. BMJ 1976; 1(6003): 221-2.
[http://dx.doi.org/10.1136/bmj.1.6003.221-c] [PMID: 764924]
[47]
Egunsola O, Choonara I, Sammons HM. Anti-epileptic drug utilisation in paediatrics: a systematic review. BMJ Paediatr Open 2017; 1(1): e000088.
[http://dx.doi.org/10.1136/bmjpo-2017-000088] [PMID: 29637124]
[48]
Akhondian J, Kiani MA, Jafari SA, Beiraghi Toosi M, Mirzaei Najm Abad M, Ahanchian H. Evaluation of liver enzymes rising in patients treated with sodium valproate (VPA). Int J Pediatr 2015; 3(3): 685-9.
[49]
Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37(3): 379-85.
[http://dx.doi.org/10.1212/WNL.37.3.379] [PMID: 3102998]
[50]
Abdella EM, Galaly SR, Mohammed HM, Khadrawy SM. Protective role of vitamin E against valproic acid-induced cytogenotoxicity and hepatotoxicity in mice. J Basic Appl Zool 2014; 67(4): 127-39.
[http://dx.doi.org/10.1016/j.jobaz.2014.03.003]
[51]
Ishtiaq O, Baqai HZ, Anwer F, Hussain N. Patterns of pancytopenia patients in a general medical ward and a proposed diagnostic approach. J Ayub Med Coll Abbottabad 2004; 16(1): 8-13.
[PMID: 15125172]
[52]
Yadav BS, Varma A, Kiyawat P. Clinical profile of pancytopenia: a tertiary care experience. Int J Bioassays 2014; 4(1): 3673-7.
[53]
Hsu H-C, Tseng H-K, Wang S-C, Wang Y-Y. Valproic acid-induced agranulocytosis. Int J Gerontol 2009; 3(2): 137-9.
[http://dx.doi.org/10.1016/S1873-9598(09)70036-5]
[54]
Mintzer DM, Billet SN, Chmielewski L. Drug-induced hematologic syndromes. Adv Hematol 2009; 2009: 495863.
[http://dx.doi.org/10.1155/2009/495863] [PMID: 19960059]
[55]
Pippenger CE. Free radical scavenging enzyme activity profiles in risk assessment of idiosyncratic drug reactions. Probable mechanism for valproate-induced acute pancreatitis and hepatotoxicity. In: Levy RH, Penry JK, Eds. Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity. New York: Raven Press 1991; pp. 75-88.
[56]
Pippenger CE. Pharmacology of neural tube defects. Epilepsia 2003; 44(Suppl. 3): 24-32.
[http://dx.doi.org/10.1046/j.1528-1157.44.s3.3.x] [PMID: 12790883]
[57]
Cengiz M, Yüksel A, Seven M. The effects of carbamazepine and valproic acid on the erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children. Pharmacol Res 2000; 41(4): 423-5.
[http://dx.doi.org/10.1006/phrs.1999.0603] [PMID: 10704266]
[58]
Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci 2005; 86(2): 427-35.
[http://dx.doi.org/10.1093/toxsci/kfi184] [PMID: 15858223]
[59]
Baran ÖP, Yıldırım A, Akkuş M. The protective role of folic acid and vitamin E against toxical effects of valproic acid on liver tissue during period of gestation. Experim Animals 2004; 14: 15.
[60]
Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, Pippenger CE. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics 1998; 29(4): 195-201.
[http://dx.doi.org/10.1055/s-2007-973560] [PMID: 9762695]
[61]
Defoort EN, Kim PM, Winn LM. Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol Pharmacol 2006; 69(4): 1304-10.
[http://dx.doi.org/10.1124/mol.105.017855] [PMID: 16377765]
[62]
Pang WW, Price EA, Sahoo D, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA 2011; 108(50): 20012-7.
[http://dx.doi.org/10.1073/pnas.1116110108] [PMID: 22123971]
[63]
Na L, Wartenberg M, Nau H, Hescheler J, Sauer H. Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen species. Birth Defects Res A Clin Mol Teratol 2003; 67(3): 174-80.
[http://dx.doi.org/10.1002/bdra.10030] [PMID: 12797459]
[64]
Aly F, Hassan N, Farghaly AA, Elsherbiny KM, Salman A. Antimutagenesis of vitamin AD3E mixture to mutations induced by flouroquinolone drug ciprofloxacin on mice. J Genet Eng Biotechnol 2009; 7(1): 35-43.
[65]
De Berardis D, Campanella D, Matera V, et al. Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. J Clin Psychopharmacol 2003; 23(5): 451-8.
[http://dx.doi.org/10.1097/01.jcp.0000088911.24613.0d] [PMID: 14520121]
[66]
Katzung BG, Trevor AJ. Basic & clinical pharmacology. 2015. Available from: http://accessmedicine.mhmedical.com/book.aspx? bookid=1193

Rights & Permissions Print Cite
Article Metrics
91
4
1
© 2024 Bentham Science Publishers | Privacy Policy